295 related articles for article (PubMed ID: 30677865)
1. Protein Kinase CK2, a Potential Therapeutic Target in Carcinoma Management.
Lian H; Su M; Zhu Y; Zhou Y; Soomro SH; Fu H
Asian Pac J Cancer Prev; 2019 Jan; 20(1):23-32. PubMed ID: 30677865
[TBL] [Abstract][Full Text] [Related]
2. Casein Kinase II (CK2) as a Therapeutic Target for Hematological Malignancies.
Gowda C; Sachdev M; Muthusami S; Kapadia M; Petrovic-Dovat L; Hartman M; Ding Y; Song C; Payne JL; Tan BH; Dovat S
Curr Pharm Des; 2017; 23(1):95-107. PubMed ID: 27719640
[TBL] [Abstract][Full Text] [Related]
3. CIGB-300: A peptide-based drug that impairs the Protein Kinase CK2-mediated phosphorylation.
Perea SE; Baladrón I; Valenzuela C; Perera Y
Semin Oncol; 2018 Jan; 45(1-2):58-67. PubMed ID: 30318085
[TBL] [Abstract][Full Text] [Related]
4. Protein kinase CK2 in health and disease: CK2: a key player in cancer biology.
Trembley JH; Wang G; Unger G; Slaton J; Ahmed K
Cell Mol Life Sci; 2009 Jun; 66(11-12):1858-67. PubMed ID: 19387548
[TBL] [Abstract][Full Text] [Related]
5. Protein kinase CK2 inhibitors: a patent review.
Cozza G; Pinna LA; Moro S
Expert Opin Ther Pat; 2012 Sep; 22(9):1081-97. PubMed ID: 22908959
[TBL] [Abstract][Full Text] [Related]
6. Casein Kinase II: an attractive target for anti-cancer drug design.
Hanif IM; Hanif IM; Shazib MA; Ahmad KA; Pervaiz S
Int J Biochem Cell Biol; 2010 Oct; 42(10):1602-5. PubMed ID: 20558317
[TBL] [Abstract][Full Text] [Related]
7. Protein kinase CK2 inhibitors: emerging anticancer therapeutic agents?
Bortolato A; Cozza G; Moro S
Anticancer Agents Med Chem; 2008 Oct; 8(7):798-806. PubMed ID: 18855581
[TBL] [Abstract][Full Text] [Related]
8. Too much of a good thing: the role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2.
Duncan JS; Litchfield DW
Biochim Biophys Acta; 2008 Jan; 1784(1):33-47. PubMed ID: 17931986
[TBL] [Abstract][Full Text] [Related]
9. Targeting CK2 for cancer therapy.
Ahmad KA; Wang G; Slaton J; Unger G; Ahmed K
Anticancer Drugs; 2005 Nov; 16(10):1037-43. PubMed ID: 16222144
[TBL] [Abstract][Full Text] [Related]
10. ATP site-directed inhibitors of protein kinase CK2: an update.
Sarno S; Papinutto E; Franchin C; Bain J; Elliott M; Meggio F; Kazimierczuk Z; Orzeszko A; Zanotti G; Battistutta R; Pinna LA
Curr Top Med Chem; 2011; 11(11):1340-51. PubMed ID: 21513497
[TBL] [Abstract][Full Text] [Related]
11. Strategies of Targeting CK2 in Drug Discovery: Challenges, Opportunities, and Emerging Prospects.
Chen Y; Wang Y; Wang J; Zhou Z; Cao S; Zhang J
J Med Chem; 2023 Feb; 66(4):2257-2281. PubMed ID: 36745746
[TBL] [Abstract][Full Text] [Related]
12. Cross-talk between the CK2 and AKT signaling pathways in cancer.
Ruzzene M; Bertacchini J; Toker A; Marmiroli S
Adv Biol Regul; 2017 May; 64():1-8. PubMed ID: 28373060
[TBL] [Abstract][Full Text] [Related]
13. CK2 inhibitor CX-4945 suppresses DNA repair response triggered by DNA-targeted anticancer drugs and augments efficacy: mechanistic rationale for drug combination therapy.
Siddiqui-Jain A; Bliesath J; Macalino D; Omori M; Huser N; Streiner N; Ho CB; Anderes K; Proffitt C; O'Brien SE; Lim JK; Von Hoff DD; Ryckman DM; Rice WG; Drygin D
Mol Cancer Ther; 2012 Apr; 11(4):994-1005. PubMed ID: 22267551
[TBL] [Abstract][Full Text] [Related]
14. Cellular regulators of protein kinase CK2.
Montenarh M
Cell Tissue Res; 2010 Nov; 342(2):139-46. PubMed ID: 20976471
[TBL] [Abstract][Full Text] [Related]
15. Antitumoral activity of allosteric inhibitors of protein kinase CK2.
Moucadel V; Prudent R; Sautel CF; Teillet F; Barette C; Lafanechere L; Receveur-Brechot V; Cochet C
Oncotarget; 2011 Dec; 2(12):997-1010. PubMed ID: 22184283
[TBL] [Abstract][Full Text] [Related]
16. Role of CK2 inhibitor CX-4945 in anti-cancer combination therapy - potential clinical relevance.
D'Amore C; Borgo C; Sarno S; Salvi M
Cell Oncol (Dordr); 2020 Dec; 43(6):1003-1016. PubMed ID: 33052585
[TBL] [Abstract][Full Text] [Related]
17. Druggability of the CK2 inhibitor CX-4945 as an anticancer drug and beyond.
Kim J; Kim SH
Arch Pharm Res; 2012 Aug; 35(8):1293-6. PubMed ID: 22941473
[TBL] [Abstract][Full Text] [Related]
18. Protein kinase CK2 inhibition as a pharmacological strategy.
Borgo C; Ruzzene M
Adv Protein Chem Struct Biol; 2021; 124():23-46. PubMed ID: 33632467
[TBL] [Abstract][Full Text] [Related]
19. [Casein kinase 2, the versatile regulator of cell survival].
Volodina IuL; Shtil' AA
Mol Biol (Mosk); 2012; 46(3):423-33. PubMed ID: 22888632
[TBL] [Abstract][Full Text] [Related]
20. Chemically induced degradation of CK2 by proteolysis targeting chimeras based on a ubiquitin-proteasome pathway.
Chen H; Chen F; Liu N; Wang X; Gou S
Bioorg Chem; 2018 Dec; 81():536-544. PubMed ID: 30245235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
